Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death

Blood

Volumn 120, Issue 23, 2012, Pages 4635-4644

  Clark, Mary C ^a   Pang, Mabel ^a   Hsu, Daniel K ^b   Liu, Fu Tong ^b   De Vos, Sven ^a   Gascoyne, Randy D ^c   Said, Jonathan ^a   Baum, Linda G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CD45 ANTIGEN; CELL SURFACE PROTEIN; DEXAMETHASONE; ETOPOSIDE; GALECTIN 3; GCS 100; POLYSACCHARIDE; PROTEIN TYROSINE PHOSPHATASE; RITUXIMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELLULAR SECRETION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 84870521155     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438234     Document Type: Article

References (52)

1. Jaffe E, Harris N, Stein H, Isaacson P. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384-4399.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909-3918.
3. Muris J, Meijer C, Ossenkoppele G, Vos W, Oudejans J. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol. 2006;24(3):97-104. (Pubitemid 44483901)
4. Shipp M, Ross K, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74. (Pubitemid 34101731)
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
6. Hoyer K, Pang M, Gui D, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004;164(3):893-902. (Pubitemid 38235471)
7. Kim S, Lee S, Sung H, et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008;120(4):211-216.
8. Andréasson U, Dictor M, Jerkeman M, et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol. 2009;84(12):803-808.
9. D'Haene N, Maris C, Sandras F, et al. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int J Immunopathol Pharmacol. 2005;18(3):431-443. (Pubitemid 41532359)
10. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635. (Pubitemid 44382499)
11. Lin CI, Whang EE, Donner DB, et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res. 2009;7(10):1655-1662.
12. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65(18):8350-8358. (Pubitemid 41330600)
13. Streetly M, Maharaj L, Joel S, Schey S, Gribben J, Cotter F. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010;115(19):3939-3948.
14. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996;93(13):6737-6742. (Pubitemid 26230379)
15. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat. 2007;10(3):101-108. (Pubitemid 47031053)
16. Clark MC, Baum LG. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci. 2012;1253:58-67.
17. Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 2004; 279(12):10841-10847. (Pubitemid 38401573)
18. Demotte N, Wieërs G, Van Der Smissen P, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010;70(19):7476- 7488.
19. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature. 2001;409(6821):733-739. (Pubitemid 32144520)
20. Earl LA, Bi S, Baum LG. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J Biol Chem. 2010;285(4):2232-2244.
21. Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A. 2011;108(26):10650-10655.
22. Shrivastava P, Katagiri T, Ogimoto M, Mizuno K, Yakura H. Dynamic regulation of Src-family kinases by CD45 in B cells. Blood. 2004;103(4):1425- 1432. (Pubitemid 38168658)
23. Stillman B, Hsu D, Pang M, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol. 2006;176(2):778-789. (Pubitemid 43099674)
24. Chen IJ, Chen HL, Demetriou M. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem. 2007;282(48):35361-35372. (Pubitemid 350232446)
25. Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis. 2010;1(11):e101.
26. Cabrera PV, Amano M, Mitoma J, et al. Haploin-sufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death. Blood. 2006;108(7):2399-2406. (Pubitemid 44497525)
27. Fukuhara K, Okumura M, Shiono H, et al. A study on CD45 isoform expression during T-cell development and selection events in the human thymus. Hum Immunol. 2002;63(5):394-404. (Pubitemid 34521371)
28. Lee SH, Yu SY, Nakayama J, et al. Core2 O-glycan structure is essential for the cell surface expression of sucrase isomaltase and dipeptidyl peptidase-IV during intestinal cell differentiation. J Biol Chem. 2010;285(48):37683-37692.
29. Marchetti MC, Di Marco B, Cifone G, Migliorati G, Riccardi C. Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood. 2003;101(2):585-593. (Pubitemid 36077581)
30. Liu J, Uematsu H, Tsuchida N, Ikeda MA. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011;10:95.
31. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol. 2007;178(4):2287-2295. (Pubitemid 46233427)
32. Fulcher JA, Chang MH, Wang S, et al. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem. 2009;284(39):26860-26870.
33. Xu Z, Weiss A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol. 2002;3(8):764-771.
34. Amano M, Galvan M, He J, Baum LG. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem. 2003;278(9):7469-7475. (Pubitemid 36800753)
35. Fouillit M, Joubert-Caron R, Poirier F, et al. Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells. Glycobiology. 2000; 10(4):413-419. (Pubitemid 30184612)
36. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry. 1998;37(12):4086-4092. (Pubitemid 28166430)
37. Lepur A, Salomonsson E, Nilsson UJ, Leffler H. Ligand induced galectin-3 protein selfassociation. J Biol Chem. 2012;287(26):21751-21756.
38. Zikherman J, Doan K, Parameswaran R, Raschke W, Weiss A. Quantitative differences in CD45 expression unmask functions for CD45 in B-cell development, tolerance, and survival. Proc Natl Acad Sci U S A. 2012;109(1):E3-E12.
39. Kobayashi T, Shimura T, Yajima T, et al. Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis. 2011;28(4):367-376.
40. Lin CI, Whang EE, Abramson MA, et al. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 2009;379(2):626-631.
41. Mazurek N, Byrd JC, Sun Y, et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2012;19(3):523-533.
42. Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 2012;188(7):3127-3137.
43. Amano M, Hashimoto R, Nishimura SI. Effects of single genetic damage in carbohydraterecognizing proteins in mouse serum N-glycan profile revealed by simple glycotyping analysis. Chembiochem. 2012;13(3):451-464.
44. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNAdependent regulatory loop. Mol Cell. 2007;27(6):992-1004. (Pubitemid 47488189)
45. Chen HD, Zhou X, Yu G, et al. Knockdown of core 1 beta 1, 3-galactosyltransferase prolongs skin allograft survival with induction of galectin-1 secretion and suppression of CD8(+) T cells: T synthase knockdown effects on galectin-1 and CD8(+) T cells. J Clin Immunol. 2012;32(4):820-836.
46. Zhang HW, Chen ZW, Li SH, Bai W, Cheng NL, Wang JF. Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma. Hematol Oncol. 2011;29(4):185-189.
47. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159-166. (Pubitemid 38821823)
48. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332-2343. (Pubitemid 350011706)
49. Glinsky VV, Kiriakova G, Glinskii OV, et al. Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia. 2009;11(9):901-909.
50. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2011;9(1):22-31.
51. Cotter F, J G, Streetly M, et al. Clinical caspase activation in CLL by GCS-100, a novel carbohydrate, in a phase 2 study. Ann Oncol (Meeting Abstracts);2008:1990(Suppl 4):iv.
52. Cotter F, Smith DA, Boyd TE, et al. Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. J Clin Oncol (Meeting Abstracts); 2009:27(15 Suppl):7006.